Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Johnson

Showing results (151-160 of 221) with videos related to

Pageof 23
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancerPhilip E Lammers, Yu Shyr, Chung-I Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10Carmela Pepe, Baktiar Hasan, Timothy L Winton, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 13, 2016
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathyAmanda M Lynn, Siddharth Singh, Stephen E Congly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10Andrea Bezjak, Christopher W Lee, Keyue Ding, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590Heather A Wakelee, Patricia Stephenson, Steven M Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599Suresh S Ramalingam, Suzanne E Dahlberg, Corey J Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
The Oncologist|November 10, 2009
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyLuigi Moretti, David S Yu, Heidi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancerRobert Mutter, Bo Lu, David P Carbone, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2007
PDGFR-beta expression in small cell lung cancer patientsEric T Shinohara, Adriana Gonzalez, Pierre P Massion, et al.
Pageof 23

Showing results (151-160 of 221) with videos related to

Sort By:
Pageof 23
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancerPhilip E Lammers, Yu Shyr, Chung-I Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10Carmela Pepe, Baktiar Hasan, Timothy L Winton, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 13, 2016
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathyAmanda M Lynn, Siddharth Singh, Stephen E Congly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10Andrea Bezjak, Christopher W Lee, Keyue Ding, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590Heather A Wakelee, Patricia Stephenson, Steven M Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599Suresh S Ramalingam, Suzanne E Dahlberg, Corey J Langer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler, Athanassios Argiris, Jyoti D Patel, et al.
The Oncologist|November 10, 2009
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyLuigi Moretti, David S Yu, Heidi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancerRobert Mutter, Bo Lu, David P Carbone, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2007
PDGFR-beta expression in small cell lung cancer patientsEric T Shinohara, Adriana Gonzalez, Pierre P Massion, et al.
Pageof 23